

OPEN

A prolonged multispecies outbreak of IMP-6 carbapenemase-producing Enterobacterales due to horizontal transmission of the IncN plasmid

Takuya Yamagishi^{1,11}, Mari Matsui^{2,11}, Tsuyoshi Sekizuka^{3,11}, Hiroaki Ito⁴, Munehisa Fukusumi^{1,4}, Tomoko Uehira⁵, Miyuki Tsubokura⁶, Yoshihiko Ogawa⁵, Atsushi Miyamoto⁷, Shoji Nakamori⁷, Akio Tawa⁸, Takahisa Yoshimura⁹, Hideki Yoshida⁹, Hidetetsu Hirokawa⁹, Satowa Suzuki², Tamano Matsui¹, Keigo Shibayama¹⁰, Makoto Kuroda³ & Kazunori Oishi^{1*}

A multispecies outbreak of IMP-6 carbapenemase-producing Enterobacterales (IMP-6-CPE) occurred at an acute care hospital in Japan. This study was conducted to understand the mechanisms of IMP-6-CPE transmission by pulsed-field gel electrophoresis (PFGE), multilocus sequence typing and whole-genome sequencing (WGS), and identify risk factors for IMP-6-CPE acquisition in patients who underwent abdominal surgery. Between July 2013 and March 2014, 22 hospitalized patients infected or colonized with IMP-6-CPE (*Escherichia coli* [n = 8], *Klebsiella oxytoca* [n = 5], *Enterobacter cloacae* [n = 5], *Klebsiella pneumoniae* [n = 3] and *Klebsiella aerogenes* [n = 1]) were identified. There were diverse PFGE profiles and sequence types (STs) in most of the species except for *K. oxytoca*. All isolates of *K. oxytoca* belonged to ST29 with similar PFGE profiles, suggesting their clonal transmission. Plasmid analysis by WGS revealed that all 22 isolates but one shared a ca. 50-kb IncN plasmid backbone with *bla*_{IMP-6} suggesting interspecies gene transmission, and typing of plasmids explained epidemiological links among cases. A case-control study showed pancreatoduodenectomy, changing drains in fluoroscopy room, continuous peritoneal lavage and enteric fistula were associated with IMP-6-CPE acquisition among the patients. Plasmid analysis of isolates in an outbreak of IMP-6-CPE suggested interspecies gene transmission and helped to clarify hidden epidemiological links between cases.

Carbapenem-resistant Enterobacterales (CRE) is one of the most worrisome antimicrobial-resistant pathogens because of the severity of disease caused, rapid spread across the world, potential to spread into the community, shortage of effective drugs and lack of drugs under development^{1–3}. The spread of certain clonal strains and epidemic resistance plasmids that carry the gene coding carbapenemase is considered to be a driving force of its rapid spread^{1,4}. However, the distribution of clonal strains of each species and the types of epidemic resistance plasmids and carbapenemase are geographically diverse^{4–6}.

CRE is still rare in Japan, where meropenem resistance (minimum inhibitory concentration [MIC] ≥ 4 $\mu\text{g}/\text{mL}$) was 0.2% among *Escherichia coli* and 0.5% among *Klebsiella pneumoniae* in 2016 based on the National Surveillance⁷. In Japan, the predominant carbapenemase detected in Enterobacterales is an IMP type metallo- β -lactamase (MBL), and sporadic cases or small outbreaks of IMP producers have been reported across

¹Infectious Disease Surveillance Center, National Institute of Infectious Diseases, Tokyo, Japan. ²Antimicrobial Resistance Research Center, National Institute of Infectious Diseases, Tokyo, Japan. ³Pathogen Genomics Center, National Institute of Infectious Diseases, Tokyo, Japan. ⁴Field Epidemiology Training Program, National Institute of Infectious Diseases, Tokyo, Japan. ⁵Department of Infectious Diseases, National Hospital Organization Osaka National Hospital, Osaka, Japan. ⁶Infection Control Team, National Hospital Organization Osaka National Hospital, Osaka, Japan. ⁷Department of Surgery, National Hospital Organization Osaka National Hospital, Osaka, Japan. ⁸Department of Pediatrics, National Hospital Organization Osaka National Hospital, Osaka, Japan. ⁹Osaka City Public Health Office, Osaka, Japan. ¹⁰Department of Bacteriology II, National Institute of Infectious Diseases, Tokyo, Japan. ¹¹These authors contributed equally: Takuya Yamagishi, Mari Matsui and Tsuyoshi Sekizuka. *email: toyamaeiken1@chic.ocn.ne.jp

the country^{8–12}. IMP producers are resistant to almost all β -lactam antibiotics, which limits treatment options. IMP-6 MBL does not hydrolyse imipenem efficiently, and its producer is usually susceptible to imipenem *in vitro* (MIC $\leq 1 \mu\text{g/mL}$)^{8,9}, which may be a risk that can be ignored in clinical laboratories. Because there is no established evidence that infection due to IMP-6 producer is treatable with imipenem, we consider it is important to control bacteria harbouring *bla*_{IMP-6} to avoid their spread without our awareness.

In July 2010, a patient with CRE was first identified at Osaka National Hospital (ONH). Subsequently, patients infected or colonized with CRE continued to be identified at the hospital despite enhanced control measures taken by the hospital infection control team. Because of the continued detection of CRE, which totalled more than 100 cases between 2010 and 2014, and affected neighbouring healthcare facilities, an investigation was initiated by the Osaka City Public Health Office (OCPHO) and the National Institute of Infectious Diseases (NIID) as a public health response in March 2014. The majority of isolates had *bla*_{IMP-6} and belonged to various species of Enterobacterales.

The objectives of this study were to describe the features of this long-standing outbreak of IMP-6 carbapenemase-producing Enterobacterales (IMP-6-CPE) outbreak through a plasmid analysis and to identify risk factors of its acquisition among patients who underwent abdominal surgery in ONH.

Materials and Methods

Setting and case definition. ONH is a tertiary referral hospital with approximately 700 beds in Osaka, Japan. It examines more than 200,000 patients every year, the majority of whom are referred from hospitals in Osaka and neighbouring prefectures. Because this investigation was conducted as a public health response to the outbreak, no informed consent was obtained from the study population. The ethical committee waived the need for written consent for the research handling the bacterial isolates.

Because the epidemiology of the outbreak and risk factors of acquiring IMP-6-CPE might be different between the early stage around 2010 and the latest stage around 2014, we focused on the cases during the nine months prior to the public health response. A case was defined as a hospitalized patient who tested positive for IMP-6-CPE from a clinical specimen at ONH between 1 July 2013 and 15 March 2014. Medical records and surgical records were reviewed for laboratory data, patient demographics characteristics and medical procedures for six months before IMP-6-CPE detection. An epidemiological link was defined as a patient sharing the same ward with another patient for at least one day, and the two wards of the Department of Surgery was considered as the same ward (E9 and W9).

Bacterial isolates. Clinical isolates of Enterobacterales identified as resistant to carbapenem (imipenem and/or meropenem $\geq 8 \mu\text{g/mL}$) or resistant to both broad-spectrum β -lactams and cephamycins by a Phoenix automated microbiology system (BD Japan, Tokyo, Japan) were screened for MBL production by a double-disk synergy test with sodium mercaptoacetate¹³ at ONH. The double-disk synergy test positive isolates at ONH were defined as suspected MBL producing Enterobacterales, and further subjected to PCR¹⁴ and Sanger sequencing at NIID to confirm the presence of *bla*_{IMP-6}. A conjugation experiment was performed using *E. coli* DH10B as a recipient by the broth-mating method. The conjugants were selected on LB agar plates containing streptomycin (800 $\mu\text{g/mL}$) and ceftazidime (16 $\mu\text{g/mL}$).

Pulsed-field gel electrophoresis (PFGE). Bacterial genomic DNA was prepared in an agarose block and digested with *Xba*I (New England Biolabs, MA, USA) for *Klebsiella oxytoca*, *K. pneumoniae* and *E. coli* and *Spe*I (New England Biolabs) for *Enterobacter cloacae*. The DNA fragments were separated in a 1% agarose slab gel by a CHEF Mapper system (Bio-Rad, CA, USA) for 24 h with a ramped pulse time of 12.6–40.1 s. DNA bands larger than 48.5 kb were detected automatically using GelCompar II software, version 6.6 (Applied Maths, St-Martens-Latem, Belgium). The Dice coefficient was used to calculate similarities, and UPGMA was used for cluster analysis.

Whole-genome sequencing (WGS) of plasmids and multilocus sequence typing (MLST). S1 nuclease-PFGE was performed as described previously¹⁵. Briefly, an agarose plug containing a bacterial genomic DNA was treated by S1 nuclease to digest circular forms of the plasmids, resulting in linearized forms. All visible plasmid and chromosomal DNA bands were excised from S1-PFGE agarose gel, and the purified DNA was subjected to DNA-Seq for paired-end short reads ($2 \times 300 \text{ mer}$) with an MiSeq Reagent Kit v3 (Illumina, San Diego, CA, USA), followed by *de novo* assembly by A5-miseq ver. 20140604¹⁶. The complete circular plasmid sequences were determined by long reads on a Sequel sequencer (PacBio, Menlo Park, CA, USA), followed by *de novo* assembly and error correction by Canu version 1.4¹⁷, minimap version 0.2-r124¹⁸, Racon version 1.1.0¹⁹, Circlator version 1.5.3²⁰ and Pilon version 1.18²¹. Gene extraction and annotation were performed by Prodigal version 2.63²², and homology searching against a public nucleotide database (NCBI nr), respectively.

To identify the bacterial sequence type, antimicrobial resistance gene and plasmid replicon type, the assembled contigs were analysed by MLST 2.0²³ and ResFinder 3.2²⁴, and PlasmidFinder 2.1²⁵, respectively.

The hierarchical cluster analysis of conserved plasmid genes was performed by usearch version 8.1.1812 with the following parameters after sorting by amino acid sequence length: -cluster_smallmem -minsl 0.8 -minqt 0.8 -maxqt 1.25 -query_cov 0.8 -target_cov 0.8²⁶, followed by visualization based on the heatmap.2 program in the gplot R package with Pearson correlation and ward.D2 clustering method. Plasmid clustering type based on conserved gene patterns was distinguished at a similarity threshold of 74%. The complete and draft sequences of the plasmids carrying *bla*_{IMP-6} were deposited in DDBJ/EMBL/GenBank as shown in the Supplementary Table.

Case-control study. Because half of the cases were patients who were admitted to the Department of Surgery, a case-control study was conducted to establish risk factors of IMP-6-CPE acquisition among patients who underwent abdominal surgery at ONH. From the observation of infection control practices in the wards of




Figure 2. Dendrogram of pulsed-field gel electrophoresis (PFGE) profiles, multilocus sequence typing (MLST) data and plasmid types for the 22 isolates from IMP-6 carbapenemase-producing Enterobacterales cases. (a) *Escherichia coli*, (b) *Klebsiella oxytoca*, (c) *Enterobacter cloacae*, (d) *Klebsiella pneumoniae*. MLST: Multilocus sequence typing.

backbone region. Although three plasmids (types B, C and D) shared an IncN plasmid region, unique structures were detected in each plasmid. One plasmid belonging to type F consisted of an IncFIB plasmid. However, the comparative plasmid analysis indicated that gene composition on IncN plasmids was well conserved among 30 plasmids isolated from China, Taiwan and Japan. The composition of AMR genes and conjugation-related genes and AMR genes, however, showed different patterns among these geographic locations (Fig. S2A,B). Especially, *bla*_{CTX-M-2} was not detected in seven plasmids isolated from China or Taiwan, and four plasmids (pIMP-SZ1501, pIMP-GZ1517, pIMP-SH1506 and pIMP-HK1500) isolated from China possessed *bla*_{IMP-4} instead of *bla*_{IMP-6} (Figs. S2B and 3). Although pKPI-6 (AB616660), which was isolated from Japan in 2008, belonged in type A, pKPI-6 indicated a deletion of 5177 bp in the highly conserved IncN backbone in this study. Furthermore, the conjugation experiments *in vitro* were performed using the representative isolates harbouring type A1 or A2 plasmid as the donor (strain MRY14-211, MRY14-225, MRY14-168 and MRY14-226). Transconjugants with *bla*_{IMP-6} were successfully obtained.

Epidemiological link by plasmid type. Cases with type A1 plasmid: Cases 1, 2, 3, 5 and 7 were from the Department of Surgery and had an epidemiological link with hospital ward E9 and W9 (Fig. 1 and cases denoted by superscript 'a' in Fig. 3), and their isolates were *E. coli* ST357, *E. coli* ST38, *E. coli* ST131 with different PFGE profiles, *E. cloacae* and *K. oxytoca*, respectively. These five isolates shared type A1 plasmid, which was consistent with the epidemiological data.

Cases with type A2 plasmid: Cases 9, 12 and 13 were from the Department of Neurosurgery and had an epidemiological link with ward E11 (Fig. 1 and denoted by superscript 'b' in Fig. 3). Although the bacterial species of IMP-6-CPE isolated from these cases were different, *K. aerogenes*, *E. cloacae* and *K. pneumoniae*, these isolates shared type A2 plasmid.




Figure 3. Possible relationship between 23 plasmid types in the 22 isolates from IMP-6 carbapenemase-producing Enterobacteriales cases, Osaka, Japan, 2013–2014 and eight other isolates in the database. Plasmid clustering was performed on the basis of gene presence–absence pattern and *intI1* structure (intact or pseudogene). Red and black bars in the heatmap indicate gene presence and absence, respectively. Information on the samples is listed in the table to the right of the heatmap. Information on the isolates from the database that had no relationship with this outbreak is shown as N/A in the column named ‘ID’. N/A: not available; ST: sequence type by multilocus sequence typing.

Cases with type E plasmids: Among the five cases with the isolates of clonally related *K. oxytoca* (Cases 5, 17, 18, 20, and 21, Fig. 2b), three cases had an epidemiological link with ward E9 and W9 (Cases 5, 17 and 18). These three isolates and the isolate of *K. pneumoniae* from the Department of Surgery (Case 19) shared type E1 plasmid (denoted by superscript ‘c’ in Fig. 3). The other two isolates of *K. oxytoca* from cases with no apparent epidemiological link with those described above had type E2 plasmid (Cases 20 and 21).

Case-control study. The case-control study showed that pancreatoduodenectomy (PD: adjusted OR [aOR]=9.5, 95% confidence interval [CI] 1.3–118.5), changing drains in the fluoroscopy room (aOR = 14.3, 95% CI 1.9–∞), continuous peritoneal lavage (aOR = 7.9, 95% CI 1.0–113.2) and enteric fistula (aOR = 8.0, 95% CI 1.5–41.9) were associated with IMP-6-CPE acquisition after adjustment by duration of hospitalization (Table 1)³¹.

Infection prevention and responses. Suboptimal standard precautions were observed in several procedures in the wards of the Department of Surgery, including changing drains in the fluoroscopy room and continuous peritoneal lavage. Across the hospital, plastic containers to collect waste fluids from nasogastric tubes, surgical drains or urine were shared among patients within wards with suboptimal disinfection. Infection control and prevention were strengthened together, strict indications for continuous peritoneal lavage were introduced, and the sharing of plastic containers for fluid/urine collection was prohibited. OCPHO coordinated the national and regional infection control experts and supported local CRE surveillance activities. No additional cases were identified as of July 2016, nearly two years after the investigation ended.

Discussion

In the present study, we described a long-standing multispecies outbreak of IMP-6-CPE in an acute care hospital in Japan. We also highlighted possible epidemiological links among patients with IMP-6-CPE through transmission of the plasmid IncN backbone shared with *bla*_{IMP-6} and possible risk factors for IMP-6-CPE acquisition.

Plasmid analysis by WGS revealed the detailed relationship between cases with IMP-6-CPE and its routes of transmission. In the past, cases infected by different species or by isolates having different PFGE profiles were considered to have no relationship even though those cases had epidemiological links. However, through plasmid analysis by WGS, we discovered hidden relationships (type A1 or A2). And for cases with the same species with related PFGE profiles but having different epidemiological links, plasmid analysis was able to distinguish these differences (type E1 and E2), which suggests a different transmission pattern. Because of the long duration of the

Factors	Case		Median	Control		Median	OR	95%CI	p	aOR*	95%CI	p
	n = 11	(%)	(IQR)	n = 24	(%)	(IQR)						
Age, years old			76 (65–78)			71 (65–77.5)			0.44			0.32
Male gender	9	(82)		15	(63)		2.7	(0.4–30.4)	0.44	2.5	(0.4–14.5)	0.31
ASA score			2 (2–2)			2 (2–2.5)			0.22			0.11
Diabetes mellitus	1	(9)		2	(8)		1.1	(0.0–23.5)	1.00	1.0	(0.1–12.3)	0.99
Endoscopy within the past 6 months	8	(73)		18	(75)		0.9	(0.1–6.9)	1.00	0.8	(0.2–4.2)	0.81
Room share with cases	7	(64)		10	(42)		2.5	(0.5–14.4)	0.29	2.2	(0.5–10.0)	0.30
ICU admission	9	(82)		16	(67)		2.3	(0.3–25.7)	0.45	2.6	(0.4–17.0)	0.32
ICU admission days			2 (1–4)			1 (0–3.5)			0.34			0.33
Pancreato-duodenectomy	6	(55)		4	(17)		6.0	(0.9–40.0)	0.04	6.4	(1.3–32.4)	0.03
Surgical site infection	11	(100)		19	(79)		—	(0.7 –)	0.16	—	—	—
Changing drains at fluoroscopy room	11	(100)		13	(54)		—	(2.2 –)	<0.01	—	—	—
Continuous peritoneal lavage	9	(82)		10	(42)		6.3	(0.9–68.6)	0.04	5.9	(1.0–34.8)	0.05
Arterial line	11	(100)		19	(80)		—	(0.7 –)	0.16	—	—	—
Central venous line	10	(91)		15	(63)		6.0	(0.6–288.8)	0.12	5.4	(0.6–51.1)	0.14
Enteric fistula	7	(64)		5	(21)		6.7	(1.1–43.1)	0.02	8.0	(1.5–41.9)	0.01
Stoma	1	(9)		10	(42)		0.1	(<0.1–1.3)	0.11	0.2	(<0.1–1.4)	0.10
Enteral feeding	6	(55)		8	(33)		2.4	(0.4–13.2)	0.28	2.6	(0.6–11.4)	0.22
Carbapenem use	2	(18)		10	(42)		0.3	(<0.1–2.1)	0.26	0.3	(0.1–1.8)	0.19
Number of cultures			7.0 (4–9)			7.5 (4.5–11.5)			0.37			
Days of hospitalization			20 (6–26)			17 (6–34.5)			0.80			

Table 1. Risk factors of acquiring IMP-6 carbapenemase-producing Enterobacterales among cases with abdominal surgery, Osaka, Japan, 2013–2014. *Adjusted by days of hospitalization. †The univariate analyses of these variables were conducted by conditional logistic regression. IQR: interquartile range; CI: confidence interval; QR: odds ratio; aOR: adjusted odds ratio; ASA: American Society of Anesthesiology; ICU: intensive care unit.

event, plasmid analysis allowed tracing of only some of the cases in this study, but the discovery of even some of the links was of great help in understanding the features of the outbreak.

The IncN plasmid appears to have played a key role in bla_{IMP-6} transmission in this outbreak although we also observed clonal spread of species. We confirmed that *E. coli* DH10B transconjugants with bla_{IMP-6} from the isolates harbouring type A1 or A2 plasmid were successfully obtained *in vitro*. Therefore, this finding indicates that the IncN plasmids carrying bla_{IMP-6} in this study are conjugative. The IncN plasmid is a conjugative plasmid reported to be part of a broad-host-range group^{32,33}. In the current event, the bla_{IMP-6} on the IncN plasmid transmitted among five species of Enterobacterales, and similar multispecies outbreak of bla_{IMP-4} harbouring Gram-negative bacteria occurred in Australia that involved in *Pseudomonas aeruginosa* and four species of Enterobacterales³⁴. The bla_{IMP-6} -positive Japanese indigenous IncN plasmid in the current event was different from the bla_{IMP-4} -positive IncN epidemic plasmid in China²⁷. There might be a geographical difference in the gene cassette in the IncN plasmid. Long duration of the event with frequent transmissions is one reason why the IncN harbouring bla_{IMP-6} spread so many different Enterobacteriaceae species in this event. However, several factors may have an influence on limiting the host-range of plasmids such as interactions with and dependence on host-encoded DNA replication proteins, ability of conjugation and existence of functional modules in plasmids³³. The observation of epidemiology and the relationship between genera, species, sequence types and plasmids types in each outbreak is essential for understanding geographical diversity and the evolution of the host-range of plasmids, and will help to achieve better control of CPE.

The case-control study showed that PD, changing drains in the fluoroscopy room, continuous peritoneal lavage and enteric fistulae were associated with acquisition of IMP-6-CPE that carried bla_{IMP-6} . The strength of this case-control study is that the association we evaluated was based on genotype, not phenotype. Therefore, the association we evaluated was the risk of bla_{IMP-6} transmission. We adjusted time at risk because it affects the acquisition of multi-drug resistant organisms³¹, but not comorbidities, because the American Society of Anesthesiologists scores of the cases and controls were similar. It is reasonable that PD, one of the most invasive surgeries in which many medical devices are used, was a risk factor because surgery and the use of invasive medical devices were reported to be risk factors of CRE acquisition^{35,36}. Poor hand hygiene of healthcare workers observed during the investigation may explain the high ORs for changing drains in the fluoroscopy room and managing the enteric fistula, two medical procedures that frequently accompany PD. From our observation, continuous peritoneal lavage also had the potential to transmit IMP-6-CPE. This is a medical procedure used for severe acute pancreatitis or necrotizing pancreatitis^{37,38}, but its effectiveness and safety have not been studied sufficiently. It requires a complex water-handling system in which the maintenance of sterile conditions is difficult and thus might also have an influence on IMP-6-CPE transmission. Further studies are needed to evaluate the effectiveness and safety

of this procedure, and to consider its risk-benefit. Several reports have shown that endoscopy can transmit CRE³⁹, but endoscopy use within the past 6 months was not associated with IMP-6-CPE acquisition in this study.

OCPHO played a pivotal role in coordinating hospital, laboratories, regional and national rapid response teams and in the implementation of local CRE surveillance. One study reported that 12.2% of patients screened were positive for CRE in Osaka after the outbreak in ONH⁴⁰. This finding suggests that CRE might have already been prevalent in the area. The unique characteristics of IMP-6-CPE showing susceptibility to imipenem would also require antimicrobial susceptibility testing for meropenem in this area. The importance of coordinated, sustainable surveillance supported by local public health centres was also stressed in many countries in the regions of the Americas, Europe, and Asia^{41–46}. The outbreak in ONH also affected the national infectious diseases surveillance system as CRE infection became one of the notifiable diseases under Infectious Diseases Control Law in Japan from September 2014⁴⁷. In this notification, carbapenem resistance was defined as a MIC of meropenem ≥ 2 $\mu\text{g}/\text{mL}$ or imipenem ≥ 2 $\mu\text{g}/\text{mL}$ plus that of cefmetazole ≥ 64 $\mu\text{g}/\text{mL}$. In 2016, 1573 cases of CRE infection were notified⁴⁸, and we started to feedback the data on the website of the institution to ensure a timely response to the event by hospitals and local public health centres.

There are several limitations to the interpretation of the present results. First, the discovery of cases was dependent on the clinical culture and sampling policy, which varied across the hospital, and some cases might have been missed. However, samples were frequently obtained and cultured in the Department of Surgery. Additionally, active screening for those patients with invasive devices was conducted in March 2014, and the situation was comprehensively evaluated at that point. Second, suspected MBL producer positive cases in which IMP-6 was not detected were excluded from the study. The screening for MBL tested positive at ONH, and the resistance gene could have been lost during subculturing and preservation. Third, the controls in the case-control study were selected based on their phenotype, and the absence of *bla*_{IMP-6} was not confirmed. However, this selection process can result in non-differential misclassification and could bias towards null association.

In this study, we described possible epidemiological links and risk factors for patients with IMP-6-CPE acquired in a single hospital by analysis of the plasmid backbone shared with *bla*_{IMP-6}. The outbreak terminated through coordinated responses with the hospital and local public health centre, even after transmission in the hospital for years. These findings provide clues to controlling CPE outbreaks in healthcare settings.

Received: 8 March 2019; Accepted: 4 February 2020;

Published online: 05 March 2020

References

- Logan, L. K. & Weinstein, R. A. The epidemiology of Carbapenem-resistant enterobacteriaceae: The impact and evolution of a global menace. *J. Infect. Dis.* **215**, S28–S36 (2017).
- Nordmann, P., Naas, T. & Poirel, L. Global spread of carbapenemase producing Enterobacteriaceae. *Emerg. Infect. Dis.* **17**, 1791–1798 (2011).
- WHO|Global priority list of antibiotic-resistant bacteria to guide research, discovery, and development of new antibiotics. WHO. Available at, <https://www.who.int/medicines/publications/global-priority-list-antibiotic-resistant-bacteria/en/> (2017)
- Mathers, A. J., Peirano, G. & Pitout, J. D. D. The role of epidemic resistance plasmids and international high-risk clones in the spread of multidrug-resistant Enterobacteriaceae. *Clin. Microbiol. Rev.* **28**, 565–591 (2015).
- Nicolas-Chanoine, M.-H., Bertrand, X. & Madec, J.-Y. Escherichia coli ST131, an Intriguing clonal group. *Clin. Microbiol. Rev.* **27**, 543–574 (2014).
- Cornaglia, G., Giamarellou, H. & Rossolini, G. M. Metallo- β -lactamases: a last frontier for β -lactams? *Lancet Infect. Dis.* **11**, 381–393 (2011).
- Japan Nosocomial Infections Surveillance (JANIS). Annual report in, <https://janis.mhlw.go.jp/english/index.asp> (2016).
- Shigemoto, N. *et al.* Emergence in Japan of an imipenem-susceptible, meropenem-resistant Klebsiella pneumoniae carrying blaIMP-6. *Diagn. Microbiol. Infect. Dis.* **72**, 109–112 (2012).
- Hirakata, Y. *et al.* Rapid detection and evaluation of clinical characteristics of emerging multiple-drug-resistant gram-negative rods carrying the metallo-beta-lactamase gene blaIMP. *Antimicrob. Agents Chemother.* **42**, 2006–2011 (1998).
- Hayakawa, K. *et al.* Molecular and epidemiological characterization of IMP-type metallo- β -lactamase-producing Enterobacter cloacae in a Large tertiary care hospital in Japan. *Antimicrob. Agents Chemother.* **58**, 3441–3450 (2014).
- Uwamino, Y. *et al.* Rapid Detection and Typing of Carbapenemase Genes from Carbapenem-Resistant Enterobacteriaceae Isolates Collected in a Japanese Hospital Using the Xpert Carba-R Assay. *Jpn. J. Infect. Dis.* **70**, 124–125 (2017).
- Ito, H. *et al.* Plasmid-mediated dissemination of the metallo-beta-lactamase gene blaIMP among clinically isolated strains of Serratia marcescens. *Antimicrob. Agents Chemother.* **39**, 824–9 (1995).
- Arakawa, Y. *et al.* Convenient test for screening metallo-beta-lactamase-producing gram-negative bacteria by using thiol compounds. *J. Clin. Microbiol.* **38**, 40–43 (2000).
- Shibata, N. *et al.* PCR typing of genetic determinants for metallo-beta-lactamases and integrases carried by gram-negative bacteria isolated in Japan, with focus on the class 3 integron. *J. Clin. Microbiol.* **41**, 5407–5413 (2003).
- Akiba, M. *et al.* Distribution and Relationships of Antimicrobial Resistance Determinants among Extended-Spectrum-Cephalosporin-Resistant or Carbapenem-Resistant Escherichia coli Isolates from Rivers and Sewage Treatment Plants in India. *Antimicrob. Agents Chemother.* **60**, 2972–2980 (2016).
- Coil, D., Jospin, G. & Darling, A. E. A5-miseq: an updated pipeline to assemble microbial genomes from Illumina MiSeq data. *Bioinformatics* **31**, 587–589 (2015).
- Koren, S. *et al.* Canu: scalable and accurate long-read assembly via adaptive k-mer weighting and repeat separation. *Genome Res.* **27**, 722–736 (2017).
- Li, H. Minimap and miniasm: fast mapping and de novo assembly for noisy long sequences. *Bioinformatics* **32**, 2103–2110 (2016).
- Vaser, R., Sović, I., Nagarajan, N. & Šikić, M. Fast and accurate de novo genome assembly from long uncorrected reads. *Genome Res.* **27**, 737–746 (2017).
- Hunt, M. *et al.* Circlator: automated circularization of genome assemblies using long sequencing reads. *Genome Biol.* **16**, 294 (2015).
- Walker, B. J. *et al.* Pilon: an integrated tool for comprehensive microbial variant detection and genome assembly improvement. *Plos One* **9**, e112963 (2014).
- Hyatt, D. *et al.* Prodigal: prokaryotic gene recognition and translation initiation site identification. *BMC Bioinformatics* **11**, 119 (2010).
- Larsen, M. V. *et al.* Multilocus sequence typing of total-genome-sequenced bacteria. *J. Clin. Microbiol.* **50**, 1355–1361 (2012).

24. Zankari, E. *et al.* Identification of acquired antimicrobial resistance genes. *J. Antimicrob. Chemother.* **67**, 2640–2644 (2012).
25. Carattoli, A. *et al.* *In silico* detection and typing of plasmids using PlasmidFinder and plasmid multilocus sequence typing. *Antimicrob. Agents Chemother.* **58**, 3895–3903 (2014).
26. Edgar, R. C. Search and clustering orders of magnitude faster than BLAST. *Bioinformatics* **26**, 2460–2461 (2010).
27. Wang, Y. *et al.* IncN ST7 epidemic plasmid carrying bla_{IMP-4} in Enterobacteriaceae isolates with epidemiological links to multiple geographical areas in China. *J. Antimicrob. Chemother.* **72**, 99–103 (2017).
28. Kayama, S. *et al.* Complete nucleotide sequence of the IncN plasmid encoding IMP-6 and CTX-M-2 from emerging carbapenem-resistant Enterobacteriaceae in Japan. *Antimicrob. Agents Chemother.* **59**, 1356–1359 (2015).
29. Chen, C.-J. *et al.* Closely Related NDM-1-Encoding Plasmids from Escherichia coli and Klebsiella pneumoniae in Taiwan. *Plos One* **9**, e104899 (2014).
30. Shen, P. *et al.* Complete nucleotide sequence of pKP96, a 67 850 bp multiresistance plasmid encoding qnrA1, aac(6′)-Ib-cr and bla_{CTX-M-24} from Klebsiella pneumoniae. *J. Antimicrob. Chemother.* **62**, 1252–1256 (2008).
31. Harris, A. D., Karchmer, T. B., Carmeli, Y. & Samore, M. H. Methodological principles of case-control studies that analyzed risk factors for antibiotic resistance: a systematic review. *Clin. Infect. Dis.* **32**, 1055–1061 (2001).
32. Pitout, J. D. D., Nordmann, P. & Poirel, L. Carbapenemase-Producing Klebsiella pneumoniae, a Key Pathogen Set for Global Nosocomial Dominance. *Antimicrob. Agents Chemother.* **59**, 5873–5884 (2015).
33. Partridge, S. R., Kwong, S. M., Firth, N. & Jensen, S. O. Mobile Genetic Elements Associated with Antimicrobial Resistance. *Clin. Microbiol. Rev.* **31** (2018).
34. Peleg, A. Y., Franklin, C., Bell, J. M. & Spelman, D. W. Dissemination of the metallo-beta-lactamase gene bla_{IMP-4} among gram-negative pathogens in a clinical setting in Australia. *Clin. Infect. Dis.* **41**, 1549–1556 (2005).
35. Gregory, C. J. *et al.* Outbreak of carbapenem-resistant Klebsiella pneumoniae in Puerto Rico associated with a novel carbapenemase variant. *Infect. Control Hosp. Epidemiol.* **31**, 476–484 (2010).
36. Sánchez-Romero, I. *et al.* Nosocomial outbreak of VIM-1-producing Klebsiella pneumoniae isolates of multilocus sequence type 15: molecular basis, clinical risk factors, and outcome. *Antimicrob. Agents Chemother.* **56**, 420–427 (2012).
37. Caronna, R. *et al.* Clinical effects of laparotomy with perioperative continuous peritoneal lavage and postoperative hemofiltration in patients with severe acute pancreatitis. *World J. Emerg. Surg.* **4**, 45 (2009).
38. Besselink, M. G. *et al.* Surgical intervention in patients with necrotizing pancreatitis. *Br. J. Surg.* **93**, 593–599 (2006).
39. O’Horo, J. C., Farrell, A., Sohail, M. R. & Safdar, N. Carbapenem-resistant Enterobacteriaceae and endoscopy: An evolving threat. *Am. J. Infect. Control* **44**, 1032–1036 (2016).
40. Yamamoto, N. *et al.* Prevalence of, and risk factors for, carriage of carbapenem-resistant Enterobacteriaceae among hospitalized patients in Japan. *J. Hosp. Infect.* **97**, 212–217 (2017).
41. Munoz-Price, L. S. *et al.* Clinical epidemiology of global expansion of *Klebsiella pneumoniae* carbapenemases. *Lancet. Infect. Dis.* **13**, 785–796 (2013).
42. Ray, M. J., Lin, M. Y., Weinstein, R. A. & Trick, W. E. Spread of Carbapenem-Resistant *Enterobacteriaceae* Among Illinois Healthcare Facilities: The Role of Patient Sharing. *Clin. Infect. Dis.* **63**, 889–893 (2016).
43. Slayton, R. B. *et al.* Vital Signs: Estimated Effects of a Coordinated Approach for Action to Reduce Antibiotic-Resistant Infections in Health Care Facilities - United States. *MMWR. Morb. Mortal. Wkly. Rep.* **64**, 826–831 (2015).
44. Toth, D. J. A. *et al.* The Potential for Interventions in a Long-term Acute Care Hospital to Reduce Transmission of Carbapenem-Resistant Enterobacteriaceae in Affiliated Healthcare Facilities. *Clin. Infect. Dis.* **65**, 581–587 (2017).
45. Grundmann, H. *et al.* Occurrence of carbapenemase-producing *Klebsiella pneumoniae* and *Escherichia coli* in the European survey of carbapenemase-producing Enterobacteriaceae (EuSCAPE): a prospective, multinational study. *Lancet. Infect. Dis.* **17**, 153–163 (2016).
46. Hsu, L. Y. *et al.* Carbapenem-resistant *Acinetobacter baumannii* and *Enterobacteriaceae* in South and Southeast Asia. *Clin. Microbiol. Rev.* **30**, 1–22 (2016).
47. National Institute of Infectious Disease. Carbapenem-resistant *Enterobacteriaceae* Infection, Japan. Infectious Disease Surveillance Center. **35**, 281–282, <https://www.niid.go.jp/niid/en/iasr-vol35-e/865-iasr/5274-tpc418.html> (2014).
48. National Institute of Infectious Disease. Carbapenem-resistant *Enterobacteriaceae* Infection, Japan. Infectious Disease Surveillance Center. **40**, 17–18, <https://www.niid.go.jp/niid/en/iasr-vol40-e/865-iasr/8625-468te.html> (2019)

Acknowledgements

We thank all of the staff at National Osaka Hospital, Osaka City Public Health Office, who were involved in the response to this event but are not listed as authors. We thank Dr Kazunori Tomono at Osaka University Hospital for his insight into the overall picture of the event and the corresponding responses. Also, we are thankful for input from Dr Lee Riley at the Division of Infectious Diseases and Vaccinology School of Public Health, University of California Berkeley on interpretation of bacteriological analysis and case-control study, and Dr Yuichiro Yahata on statistical analysis. All authors revised, reviewed, and approved the final report. This research was supported by H26-Tokubetu-Shitei-005 and AMED under Grant Numbers JP16fk0108305 and JP17fk0108121.

Author contributions

T.Y., H.I., M.F., T.U., M.T., T.M. and K.O. conceived and designed the study. T.Y., M.M., T.S., H.I., M.F., T.U., M.T., M.K. and S.S. analysed the data. M.M., T.S., M.K. and S.S. generated bacteriological data including whole genome sequencing. T.Y., H.I., M.F., T.U., M.T., Y.O., A.M., S.N., A.T., T.Y., H.Y., H.H. and H.H. collected epidemiological data. T.Y., M.M., T.S., M.F., M.K., S.S. and T.M. prepared the manuscript with contributions from K.S., T.M. and K.O.

Competing interests

The authors declare no competing interests.

Additional information

Supplementary information is available for this paper at <https://doi.org/10.1038/s41598-020-60659-2>.

Correspondence and requests for materials should be addressed to K.O.

Reprints and permissions information is available at www.nature.com/reprints.

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.



Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit <http://creativecommons.org/licenses/by/4.0/>.

© The Author(s) 2020